Status:
WITHDRAWN
Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra
Lead Sponsor:
Bucci Laser Vision Institute
Conditions:
Dry Eye
Eligibility:
All Genders
60+ years
Phase:
PHASE4
Brief Summary
To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and postoperative cataract patients.
Detailed Description
Single-center, prospective, randomized, investigator-initiated study 250 cataract patients, aged 60 or older, will be tested for ocular surface inflammation with the InflammaDry® immunoassay Patient...
Eligibility Criteria
Inclusion
- Positive for MMP-9 bilaterally as assessed by the Inflammadry assay
Exclusion
- Negative Inflammadry assay in either eye
- Active diabetic retinopathy, uncontrolled glaucoma, uncontrolled uveitic inflammation
- Ocular surface diseases that might confound the interpretation of the InflammaDry assay
Key Trial Info
Start Date :
May 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 25 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04120987
Start Date
May 31 2021
End Date
June 25 2022
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bucci Laser Vision
Wilkes-Barre, Pennsylvania, United States, 18702